Ricevi le ultime notizie sulle azioni Evaxion con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di EVAX

Ultime notizie per

EVAXION A/S

Evaxion Biotech

Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

AREN

CSTM

EVAX

GDYN

GEAR

VIRX

Le azioni di Constellium, Viracta, Evaxion, Arena e Grid Dynamics mostrano movimenti significativi nella sessione di pre-market di oggi.

Pre-market: 5 titoli da monitorare oggi, 27 dicembre 2024

Evaxion AS

Financing

Press Releases

Evaxion finalizes agreement with EIB to convert debt into equity

Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Small Cap

Opinion

Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments

Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025

Evaxion announces business update and second quarter 2025 financial results

Evaxion to present at several conferences during the second half of 2025

Penny Stocks

Evaxion out-licenses vaccine candidate EVX-B3 to MSD

Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting

Evaxion expands AI-Immunology™ platform with automated vaccine design module

Biotech

General

Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

AGEN

CELC

LYEL

ONCY

TSX:ONC

ABVC BioPharma

Aligos Therapeutics

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

BeyondSpring

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

CervoMed

CEL-SCI

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

Evaxion

Gain Therapeutics

MiNK Therapeutics

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

Lite Strategy

OKYO Pharma

OS Therapies

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

PMV Pharma

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Plus Therapeutics

Sutro Biopharma

XBiotech

X4 Pharmaceuticals

HC Wainwright & Co.

Lake Street

Ladenburg Thalmann

Oppenheimer

Comments

Evaxion Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO